[go: up one dir, main page]

WO2007002912A3 - Anti-proliferative compounds, compositions, and methods of use thereof - Google Patents

Anti-proliferative compounds, compositions, and methods of use thereof Download PDF

Info

Publication number
WO2007002912A3
WO2007002912A3 PCT/US2006/025726 US2006025726W WO2007002912A3 WO 2007002912 A3 WO2007002912 A3 WO 2007002912A3 US 2006025726 W US2006025726 W US 2006025726W WO 2007002912 A3 WO2007002912 A3 WO 2007002912A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
independently
groups
substituted
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/025726
Other languages
French (fr)
Other versions
WO2007002912A2 (en
Inventor
Xiaoqin Cheng
Gary P Cook
Manoj C Desai
Edward Doerffler
Gong-Xin He
Choung U Kim
William A Lee
John C Rohloff
Jianying Wang
Zheng-Yu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/170,247 external-priority patent/US20060030545A1/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of WO2007002912A2 publication Critical patent/WO2007002912A2/en
Publication of WO2007002912A3 publication Critical patent/WO2007002912A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 is RX; RX2 is alkenyl of 2 to 18 carbon atoms or alkynyl of 2 to 18 carbon atoms; Y1 is = O, -O(RX), =S, -N(RX), -N(O)(RX), -N(ORX), -N(O)(ORX), or -N(N(RX)(RX)); RX is independently R1, R2, R4, W3, or a protecting group; R1 is independently -H or alkyl of 1 to 18 carbon atoms; R2 is independently R3 or R4 wherein each R4 is independently substituted with 0 to 3 R3 groups or taken together at a carbon atom, two R2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R3 groups; R3 is R3a, R3b, R3c or R3d, provided that when R3 is bound to a heteroatom, then R3 is R3c or R3d; R3a is -H, -F, -Cl, -Br, -I, -CF3, -CN, N3, -NO2 or -OR4; R3b is = O, -O(R4), =S, -N(R4), -N(O)(R4), -N(OR4), -N(O)(OR4), or -N(N(R4)(R4)); 3c is -R4, -N(R4)(R4), -SR4, -S(O)R4, -S(O)2R4, -S(O)(OR4), -S(O)2(OR4), -OC(R3b)R4, -OC(R3b)OR4, -OC(R3b)(N(R4)(R4)), -SC(R3b)R4, -SC(R3b)OR4, -SC(R3b)(N(R4)(R4)), -N(R4)C(R3b)R4, -N(R4)C(R3b)OR4, -N(R4)C(R3b)(N(R4)(R4)), W3 or -R5W3 ; R3d is -C(R3b)R4, -C(R3b)OR4, -C(R3b)W3, -C(R3b)OW3 or -C(R3b)(N(R4)(R4)); R4 is -H, or an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms; R5 is alkylene of 1 to 18 carbon atoms, alkenylene of 2 to 18 carbon atoms, or alkynylene of 2 to 18 carbon atoms; W3 is W4 or W5; W4 is R6, -C(R3b)R6, -C(R3b)W5, -SOM2R6, or -SOM2W5, wherein R6 is R4 wherein each R4 is substituted with O to 3 R3 groups; W5 is carbocycle or heterocycle wherein W5 is independently substituted with O to 3 R2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof.
PCT/US2006/025726 2005-06-29 2006-06-29 Anti-proliferative compounds, compositions, and methods of use thereof Ceased WO2007002912A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/170,247 2005-06-29
US11/170,247 US20060030545A1 (en) 2003-12-30 2005-06-29 Anti-proliferative compounds, compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2007002912A2 WO2007002912A2 (en) 2007-01-04
WO2007002912A3 true WO2007002912A3 (en) 2007-06-28

Family

ID=37173806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/025726 Ceased WO2007002912A2 (en) 2005-06-29 2006-06-29 Anti-proliferative compounds, compositions, and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2007002912A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344555B2 (en) 2014-09-15 2022-05-31 The Regents Of The University Of California Nucleotide analogs
US11572377B2 (en) 2015-09-15 2023-02-07 The Regents Of The University Of California Nucleotide analogs

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI444384B (en) 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
DK3578563T3 (en) * 2011-12-22 2021-05-31 Geron Corp Guanine analogs as telomerase substrates and telomere length influencers
CN107312039B (en) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 A kind of preparation method of tenofovir prodrug
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
WO2017106069A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
JP2020504734A (en) 2016-12-22 2020-02-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antiviral benzyl-amine phosphodiamide compounds
MA47094A (en) 2016-12-22 2021-05-26 Idenix Pharmaceuticals Llc TENOFOVIR ANTIVIRAL ALIPHATIC ESTER MEDICINAL PRODUCTS
US11826375B2 (en) 2018-07-19 2023-11-28 Merck Sharp & Dohme Llc Phosphinic amide prodrugs of tenofovir
WO2024020127A1 (en) 2022-07-21 2024-01-25 Antiva Biosciences, Inc. Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066189A1 (en) * 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066189A1 (en) * 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
US20050222090A1 (en) * 2003-12-30 2005-10-06 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
US20060046981A1 (en) * 2003-12-30 2006-03-02 Gilead Sciences, Inc. Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HOLY, ANTONIN ET AL: "Synthesis and cytostatic activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, 2,6-diaminopurines and related compounds", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS , 66(10), 1545-1592 CODEN: CCCCAK; ISSN: 0010-0765, 2001, XP009054316 *
KEITH, KATHY A. ET AL: "Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , 47(7), 2193-2198 CODEN: AMACCQ; ISSN: 0066-4804, 2003, XP002327373 *
SNOECK, R. ET AL: "Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , 46(11), 3356-3361 CODEN: AMACCQ; ISSN: 0066-4804, 2002, XP002327372 *
VALERIANOVA M ET AL: "ANTITUMOUR ACTIVITY OF N6-SUBSTITUTED PMEDAP DERIVATIVES AGAINST T-CELL LYMPHOMA", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 21, no. 3B, May 2001 (2001-05-01), pages 2057 - 2064, XP009071015, ISSN: 0250-7005 *
VALERIANOVA M ET AL: "PMEDAP AND ITS N6-SUBSTITUTED DERIVATIVES: GENOTOXIC EFFECT AND APOPTOSIS IN IN VITRO CONDITIONS", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 23, no. 6C, November 2003 (2003-11-01), pages 4933 - 4940, XP009071017, ISSN: 0250-7005 *
ZIDEK, ZDENEK ET AL: "Immunobiological activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, and 2,6-diaminopurines", EUROPEAN JOURNAL OF PHARMACOLOGY , 475(1-3), 149-159 CODEN: EJPHAZ; ISSN: 0014-2999, 2003, XP002405408 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344555B2 (en) 2014-09-15 2022-05-31 The Regents Of The University Of California Nucleotide analogs
US11572377B2 (en) 2015-09-15 2023-02-07 The Regents Of The University Of California Nucleotide analogs

Also Published As

Publication number Publication date
WO2007002912A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
CA2550222A1 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
WO2007002912A3 (en) Anti-proliferative compounds, compositions, and methods of use thereof
NZ596615A (en) Substituted isoquinoline derivative
WO2008111239A1 (en) Antistatic agent and use thereof
AR062176A1 (en) DERIVATIVES OF NICOTINAMIDE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND ITS USE TO TREAT DISEASES ASSOCIATED WITH SMOOTH MUSCLE MISCLE OR NON MUSCULAR
WO2008083252A3 (en) Methods of use for cyclopamine analogs
BRPI0415374A (en) use of a compound, compound, process for preparing it, pharmaceutical composition, process for preparing it, and, product
AR067613A1 (en) PK-DNA INHIBITORS, USE AND SYNTHESIS OF THE SAME
NO20074071L (en) Hydrazinomethyl, hydrozonomethyl and 5-membered heterocyclic compounds which act as MTOR inhibitors and their use as anti-cancer agents
AR063545A1 (en) DERIVATIVES OF TIAZOLS -1,3 AMINOSUSTITUIDOS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USES AS ANTICANCER AGENTS
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
BRPI0809981A2 (en) COMPOUNDS, THE MANUFACTURING PROCESS OF THESE, PHARMACEUTICAL COMPOSITION CONTAINING THEM, METHOD OF TREATMENT AND / OR PREVENTION OF DISEASES WHICH ARE ASSOCIATED WITH MODULATION OF SUBSTITE 5 RECEIVERS AND USE OF COMPOUNDS.
WO2008081096A3 (en) Quinolinyl derivatives, method for preparing same, pharmaceutic compositions containing same, and use thereof as hypoglycemiant and hypolipemiant agents
WO2008044054A3 (en) Hydroxy-substituted benzoic acid amide compounds for use in therapy
WO2008006044A3 (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
UA95972C2 (en) Aminopyridine derivatives having aurora a selective inhibitory action
BRPI0817168A2 (en) "method for the preparation of a compound"
WO2007022934A3 (en) Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors
MX2010006787A (en) Halogenated analogues of anti-fibrotic agents.
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
WO2008006969A3 (en) Novel tetracyclic derivatives, process for the preparation thereof and pharmaceutical compositions which contain them
BR112014002805A2 (en) composition with better scratch visibility and low surface stickiness
WO2007025897A3 (en) Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives
PT1994134E (en) Stabilized, non-aqueous cleaning compositions for microelectronics substrates
IL226276A0 (en) Process for the preparation of beta-santalol and derivatives thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06786058

Country of ref document: EP

Kind code of ref document: A2